OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

202296 citationsJournal Articlehybrid Open Access

Authors

Melissa M. Hardesty · Alaska Women's Cancer Care

Thomas C. Krivak · Western Pennsylvania Hospital

Gail S. Wright · Florida Cancer Specialists & Research Institute

Erika Hamilton · Sarah Cannon

Evelyn Fleming · Dartmouth–Hitchcock Medical Center

J Belotte · GlaxoSmithKline (United States)

Erika Krasnickas Keeton

Abstract

Niraparib + bevacizumab first-line maintenance therapy displayed promising PFS results. Safety was consistent with the known safety profiles of niraparib and bevacizumab as monotherapy.

Topics & Keywords

PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment Viral-associated cancers and disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gynecologic Oncology

Volume 166, Issue 2, pp. 219-229

DOI: 10.1016/j.ygyno.2022.05.020

Field-Weighted Citation Impact: 9.52